Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Stem Cells. Apr 26, 2014; 6(2): 239-247
Published online Apr 26, 2014. doi: 10.4252/wjsc.v6.i2.239
Published online Apr 26, 2014. doi: 10.4252/wjsc.v6.i2.239
Familial Alzheimer’s disease modelling using induced pluripotent stem cell technology
Lisa Mohamet, Natalie J Miazga, Christopher M Ward, Stem Cell Biology Group, Core Technology Facility, Faculty of Human and Medical Sciences, The University of Manchester, Manchester M13 9NT, United Kingdom
Author contributions: Mohamet L, Miazga NJ and Ward CM contributed to research, writing and editing of paper.
Supported by United Kingdom Biotechnology and Biosciences Research Council, Engineering and Physical Sciences Research Council and the Technology Strategy Board
Correspondence to: Dr. Christopher M Ward, Stem Cell Biology Group, Core Technology Facility, Faculty of Human and Medical Sciences, The University of Manchester, Manchester, 46 Grafton Street, Manchester M13 9NT, United Kingdom. christopher.ward@manchester.ac.uk
Telephone: +44-161-2755182 Fax: +44-161-2755182
Received: December 4, 2013
Revised: February 7, 2014
Accepted: February 18, 2014
Published online: April 26, 2014
Processing time: 144 Days and 20.2 Hours
Revised: February 7, 2014
Accepted: February 18, 2014
Published online: April 26, 2014
Processing time: 144 Days and 20.2 Hours
Core Tip
Core tip: Alzheimer’s disease (AD) affects 36 million people worldwide and is set to double by 2030. Progress in understanding AD has been hindered by a lack of suitable in vitro and in vivo models reflected in > 90% drug attrition rates. Induced pluripotent stem cells are an alternative source of neural cells that can be derived from patients’ somatic cells and exhibit AD pathophysiological phenotypes. These cells are amenable to HTS formats required for drug discovery applications. Harnessing this combined potential would provide an unprecedented opportunity to significantly reduce timeframes and costs associated with developing novel therapeutics, ultimately improving patient outcomes.